Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

被引:13
作者
Batteux, Benjamin [1 ,2 ,3 ,4 ]
Bennis, Youssef [1 ,3 ]
Bodeau, Sandra [1 ,3 ]
Masmoudi, Kamel [1 ]
Hurtel-Lemaire, Anne-Sophie [1 ]
Kamel, Said [3 ,5 ]
Gras-Champel, Valerie [1 ,3 ]
Liabeuf, Sophie [1 ,3 ]
机构
[1] Amiens Univ, Dept Pharmacol, Med Ctr, F-80054 Amiens, France
[2] St Quentin Med Ctr, Dept Rheumatol, F-02321 St Quentin en Yvelines, France
[3] Jules Verne Univ Picardie, MP3CV Lab, EA7517, F-80054 Amiens, France
[4] Amiens Picardie Univ, RECIF, Med Ctr, F-80054 Amiens, France
[5] Amiens Univ, Biochem Lab, Med Ctr, F-80000 Amiens, France
关键词
Osteoporosis; Drug; Pharmacology; Pharmacoepidemiology; Pharmacovigilance; BONE-MINERAL DENSITY; RHEUMATOID-ARTHRITIS PATIENTS; LOW-DOSE METHOTREXATE; POSTMENOPAUSAL WOMEN; FRACTURE RISK; VITAMIN-A; PSYCHOTROPIC MEDICATIONS; INADEQUATE RESPONSE; MULTIPLE-SCLEROSIS; SIGNAL GENERATION;
D O I
10.1016/j.bone.2021.116137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bone remodeling is a complex process, and many conditions (including drug exposure) lead to osteoporosis. Here, we sought to detect new disproportionality signals for drugs associated with osteoporosis. Methods: We performed a disproportionality analysis of the World Health Organization's VigiBase (R) pharmacovigilance database through April 12, 2020. The frequency of reports on osteoporosis for all identified drug classes was compared with that for all other drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. Results: Of the 7,594,968 cases spontaneously recorded to VigiBase (R), 4758 concerned osteoporosis. New disproportionality signals with a pharmacologically plausible mechanism were found for drugs used in neurology (levodopa (ROR [95%CI]: 10.18 [4.33-25.10]), selective serotonin agonists (4.22 [2.34-7.00]) and memantine (4.10 [1.56-8.93])), hematology (romiplostim (4.93 [1.15-21.10])), pulmonology (macitentan (3.02 [1.84-4.90])), ophthalmology (ranibizumab (3.31 [1.00-10.51])) and rheumatology (tofacitinib (3.65 [3.00-4.40])). The robustness of these new results is supported by the significant RORs for the vast majority of drugs already known to induce osteoporosis and/or increase the fracture risk, namely glucocorticoids, gonadotropin-releasing hormone analogs, anti-aromatases, androgen receptor blockers, thyroid hormones, proton pump inhibitors, thiazolidinediones, vitamin K antagonists, loop diuretics, protease inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, and enzyme-inducing antiepileptics including barbiturates and derivatives, hydantoin derivatives, carboxamide derivatives and fatty acid derivatives. Conclusion: We established up a comprehensive list of drugs potentially associated with osteoporosis and highlighted those with pharmacologically plausible mechanisms leading to bone fragility. Our results might pave the way for additional exploration of these mechanisms.
引用
收藏
页数:11
相关论文
共 35 条
[31]   Adverse drug reactions associated with ivermectin use for COVID19 reported in the World Health Organization's pharmacovigilance database [J].
Campillo, Jeremy T. ;
Faillie, Jean-Luc .
THERAPIE, 2022, 77 (06) :747-749
[32]   Anticancer drug-induced life-threatening ventricular arrhythmias: a World health Organization pharmacovigilance study [J].
Salem, Joe-Elie ;
Nguyen, Lee S. ;
Moslehi, Javid J. ;
Ederhy, Stephane ;
Lebrun-Vignes, Benedicte ;
Roden, Dan M. ;
Funck-Brentano, Christian ;
Gougis, Paul .
EUROPEAN HEART JOURNAL, 2021, 42 (38) :3915-+
[33]   IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis [J].
Alroobaea, R. ;
Rubaiee, S. ;
Hanbazazah, A. S. ;
Jahrami, H. ;
Garbarino, S. ;
Damiani, G. ;
Wu, J. ;
Bragazzi, N. L. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (11) :4074-4081
[34]   Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database [J].
Qing, Guangwei ;
Ye, Shiyi ;
Wei, Bo ;
Yang, Yuanjian .
BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01)
[35]   Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database [J].
Prevost, Rachel ;
Chretien, Basile ;
Minoc, Elise-Marie ;
Dolladille, Charles ;
Da-Silva, Angelique ;
Nehme, Ahmad ;
Joly, Florence ;
Lelong-Boulouard, Veronique ;
Bastien, Etienne .
FRONTIERS IN PHARMACOLOGY, 2023, 14